“…Since the cytoferon dose (2 IU/ml) [3] was the same as the IFN titer in the plasma of patients with multiple sclerosis and the IFN content in the human leukocyte preparation (50 IU/ml) [6], evaluated by the biological activity of the factor, was only two logarithmic units higher than the IFN titer in the patients' autologous serum, the comparable magnitudes of the effects elicited by the a-IFN preparations [3,6], and the extent of changes in the NK activity of patients with multiple sclerosis after treatment with IFN-containing autologous plasma, suggest that in multiple sclerosis serum factors other than IFN are involved in the stimulation of cytotoxicity at high effector :target ratios, whereas at low effector:target ratios the NK activity is regulated by IFN itself.…”